175 related articles for article (PubMed ID: 26418895)
1. The efficacy and safety of Endostar combined with chemoradiotherapy for patients with advanced, locally recurrent nasopharyngeal carcinoma.
Guan Y; Li A; Xiao W; Liu S; Chen B; Lu T; Zhao C; Han F
Oncotarget; 2015 Oct; 6(32):33926-34. PubMed ID: 26418895
[TBL] [Abstract][Full Text] [Related]
2. Intensity-modulated radiotherapy combined with endostar has similar efficacy but weaker acute adverse reactions than IMRT combined with chemotherapy in the treatment of locally advanced nasopharyngeal carcinoma.
Kang M; Wang F; Liao X; Zhou P; Wang R
Medicine (Baltimore); 2018 Jun; 97(25):e11118. PubMed ID: 29924009
[TBL] [Abstract][Full Text] [Related]
3. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and adverse reactions of IMRT combined with Endostar versus IMRT combined with chemotherapy for locally advanced nasopharyngeal carcinoma: a retrospective study.
Chen W; Wang F; Yang Z; Zhang T; Shen M; Wang R; Kang M
Ann Palliat Med; 2021 Nov; 10(11):11891-11900. PubMed ID: 34872313
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of a phase II randomized controlled trial comparing intensity-modulated radiotherapy with or without weekly cisplatin for the treatment of locally recurrent nasopharyngeal carcinoma.
Guan Y; Liu S; Wang HY; Guo Y; Xiao WW; Chen CY; Zhao C; Lu TX; Han F
Chin J Cancer; 2016 Feb; 35():20. PubMed ID: 26879049
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.
Hua YJ; Han F; Lu LX; Mai HQ; Guo X; Hong MH; Lu TX; Zhao C
Eur J Cancer; 2012 Dec; 48(18):3422-8. PubMed ID: 22835782
[TBL] [Abstract][Full Text] [Related]
7. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
[TBL] [Abstract][Full Text] [Related]
8. Intensity-modulated radiation therapy (IMRT)-based concurrent chemoradiotherapy (CCRT) with Endostar in patients with pelvic locoregional recurrence of cervical cancer: Results from a hospital in the Qinghai-Tibet Plateau.
Zhang K; Wang H; Wang Z; Li F; Cui Y; Ma S; Chen R; Wang Y; Guo S; Wei Y
Medicine (Baltimore); 2020 Dec; 99(49):e21966. PubMed ID: 33285664
[TBL] [Abstract][Full Text] [Related]
9. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
Ng WT; Ngan RKC; Kwong DLW; Tung SY; Yuen KT; Kam MKM; Sze HCK; Yiu HHY; Chan LLK; Lung ML; Lee AWM
Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):630-638. PubMed ID: 29413277
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiation therapy in the salvage of locally recurrent nasopharyngeal carcinoma.
Qiu S; Lin S; Tham IW; Pan J; Lu J; Lu JJ
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):676-83. PubMed ID: 22024207
[TBL] [Abstract][Full Text] [Related]
11. A Retrospective Study to Compare Five Induction Chemotherapy Regimens Prior to Radiotherapy in the Reduction of Regional Lymph Node Size in Patients with Nasopharyngeal Carcinoma.
Chen J; Qi J; Yu B; Peng XH; Wang F; Tan JJ; Chen QQ; Peng XY; Zeng FF; Liu X
Med Sci Monit; 2018 Apr; 24():2562-2568. PubMed ID: 29697098
[TBL] [Abstract][Full Text] [Related]
12. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma.
Lu TX; Mai WY; Teh BS; Zhao C; Han F; Huang Y; Deng XW; Lu LX; Huang SM; Zeng ZF; Lin CG; Lu HH; Chiu JK; Carpenter LS; Grant WH; Woo SY; Cui NJ; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):682-7. PubMed ID: 14967420
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human endostatin injection (Endostar) combined with PF chemotherapy and sequential intensity-modulated radiotherapy is tolerable and improves prognosis of locally advanced nasopharyngeal carcinoma: a randomized, open, multicenter phase II clinical study.
Xu L; Li D; Ji J; Chen Z; Tang X; Chen D; Li X; Bao D; Yan F; Pang Y; Liu S; Zhou Y; Xu X
Am J Cancer Res; 2022; 12(10):4622-4636. PubMed ID: 36381335
[TBL] [Abstract][Full Text] [Related]
14. Dose delivery analysis of weekly versus 3-weekly cisplatin concurrent with radiation therapy for locally advanced nasopharyngeal carcinoma (NPC).
Jagdis A; Laskin J; Hao D; Hay J; Wu J; Ho C
Am J Clin Oncol; 2014 Feb; 37(1):63-9. PubMed ID: 23111356
[TBL] [Abstract][Full Text] [Related]
15. Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study.
Xiao WW; Huang SM; Han F; Wu SX; Lu LX; Lin CG; Deng XW; Lu TX; Cui NJ; Zhao C
Cancer; 2011 May; 117(9):1874-83. PubMed ID: 21509764
[TBL] [Abstract][Full Text] [Related]
16. [Clinical results of recombinant human endostatin combined with chemoradiotherapy for locally advanced nasopharyngeal carcinoma].
Li Y; Jin F; Wu W; Long J; Gong X; Chen G; Bi T; Li Z; He Q; Ma F; Wang R
Zhonghua Zhong Liu Za Zhi; 2015 Feb; 37(2):128-32. PubMed ID: 25975690
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemotherapy followed by concurrent chemo-radiation therapy in locally advanced nasopharyngeal carcinoma.
Al-Amro A; Al-Rajhi N; Khafaga Y; Memon M; Al-Hebshi A; El-Enbabi A; El-Husseiny G; Radawi A; Belal A; Allam A; El-Sebaie M
Int J Radiat Oncol Biol Phys; 2005 Jun; 62(2):508-13. PubMed ID: 15890594
[TBL] [Abstract][Full Text] [Related]
18. Experience of weekly cisplatin concurrent with intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma patients with resistance to neoadjuvant chemotherapy.
Chen C; Chen T; Huang C; Wang J; Fei Z
Medicine (Baltimore); 2017 Nov; 96(44):e8434. PubMed ID: 29095283
[TBL] [Abstract][Full Text] [Related]
19. Concurrent chemoradiotherapy in locoregionally recurrent nasopharyngeal carcinoma.
Poon D; Yap SP; Wong ZW; Cheung YB; Leong SS; Wee J; Tan T; Fong KW; Chua ET; Tan EH
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1312-8. PubMed ID: 15275714
[TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma: interim results from 2 prospective phase 2 clinical trials.
Kong L; Hu C; Niu X; Zhang Y; Guo Y; Tham IW; Lu JJ
Cancer; 2013 Dec; 119(23):4111-8. PubMed ID: 24037893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
